Not all patients follow the same path: Swedish study identifies two long-term disease trajectories

Not all patients follow the same path: Swedish study identifies two long-term disease trajectories

Publication date on this website: 7 October 2026.
Date of the original paper: 24 July 2026.

Introduction
A large Swedish population-based study investigated how sarcoidosis develops during the first five years after diagnosis. The results support the understanding that the disease does not behave in the same way in all patients and that the initial clinical picture may help with earlier risk assessment.

Extended summary
The authors analyzed 9,665 people with newly diagnosed sarcoidosis in Swedish national registries. Statistical modeling of sarcoidosis-related visits identified two main trajectories. In 71.5% of patients, the number of such visits fell rapidly and approached zero within two years, corresponding to a resolving disease trajectory. In 28.5% of patients, visits remained elevated for at least five years, corresponding to a chronic trajectory.

A higher risk of a chronic course was associated with the need for immunosuppressive treatment around the time of diagnosis, older age, and certain patterns of organ involvement, including neurological, ocular, and cardiac sarcoidosis. In an additional cohort, Löfgren syndrome and HLA-DRB1*03 were associated with the resolving trajectory. The chronic trajectory was associated with a higher risk of some long-term outcomes, including infections, heart failure, diabetes, depression, anxiety, and earlier mortality.

What is new
In a large population-based sample, the study demonstrated two recognizable long-term disease trajectories and linked them to clinical characteristics at the start of the disease. This may help in developing earlier risk assessments, but it does not mean that an individual patient's course can be predicted with certainty in advance from a single finding.

Why it matters to people with sarcoidosis and clinicians
For people with sarcoidosis, the results help explain why the need for follow-up and treatment differs among people with the same diagnosis. For clinicians, the findings provide an epidemiological basis for considering the intensity of monitoring, especially when the disease is multisystem from the outset or requires immunosuppression. The results also support the importance of collaboration between pulmonologists and other specialists according to the organ affected.

Limitations of the evidence
The study relies mainly on administrative registries and the frequency of healthcare visits, which is not the same as directly measuring disease activity, symptoms, or lung function. The cohort was Swedish, so the results may not fully apply to other populations. The association between early treatment and a chronic trajectory does not prove that treatment caused chronicity; it may be a marker of more severe disease at the start.

Conclusion
Sarcoidosis has different long-term trajectories. Early recognition of features associated with a chronic course may improve follow-up planning, but risk assessment must remain individual and based on the complete clinical picture.

Source and bibliographic details
Rossides M, Kullberg S, Darlington P, et al. Sarcoidosis data-driven patient trajectories and predictors of chronic disease. Respiratory Research. 2026;27:292. Published 24 July 2026. DOI: 10.1186/s12931-026-03830-z.
Source: https://doi.org/10.1186/s12931-026-03830-z

Medical note
This text is for informational purposes and does not replace a medical examination, diagnosis, or individualized advice. Percentages from a population-based study cannot determine an individual person's prognosis on their own. Discuss the plan for follow-up and treatment with your doctor.